Amsterdam, the Netherlands – 27 August 2019

Esperite N.V. (Euronext: ESP) and Myrisoph Capital Inc (Myrisoph) are pleased to announce that they have concluded a strategic agreement related to Cryo-Save’s stem cell cryopreservation business. Myrisoph becomes the exclusive global licensee of the CryoSave brand for a minimum period of ten (10) years. Along with Cryo-Save’s long-established quality history and service, the transaction leverages Myrisoph Capital’s experience and success in turning around Medical, Laboratory and Biotech companies – including Cryo-Save Arabia, the first Stem Cell Bank in the Middle-East and North Africa region, and currently one of the more profitable cord blood banks worldwide.
Cryo-Save is one of the largest and longest operating stem cell banks in Europe, having stored more than 330.000 umbilical cord blood samples and tissues over the past 20 years.
As Part of the transaction, Myrisoph Capital takes over the responsibility for the marketing and sales of the brand as well as the storage of all samples stored to date, to continue serving the clients with the utmost care.
Myrisoph will also revitalize the brand with the explicit goal of ranking CryoSave to the top 5 Family Stem Cell Banks worldwide.
“We are excited about  the acquisition of Cryo-Save’s global business. For more than 14 years we own and manage a profitable and very successful Family Stem Cell Bank. We are confident that our management team will turn Cryo-Save into a global leader by implementing our best practices. to. We have the financial resources to invest substantially in the growth of the business for the benefit of all our current and future clients. We will conduct laboratory and storage operations in Switzerland under the highest Swiss and global standards. Our priority will be to ensure that existing and future clients will be fully satisfied. We will immediately implement the necessary changes to provide world class and reliable service that the Cryo-Save brand has come to represent” – commented Hassan Alhassani, the President of Myrisoph Capital Inc.

Esperite will convene an extraordinary shareholders' meeting within the next couple of weeks.

About the ESPERITE:
ESPERITE Group (Euronext: ESP), listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.
To learn more about ESPERITE Group, or to book an interview with CEO Frederic Amar: +31 575 548 998 – or visit the website at

Myrisoph Capital Inc, is a privately owned investment holding company based in Los-Angeles with a successful track record in turning around undervalued companies in the Medical, Laboratory, and Biotech Sectors.
To learn more about Myrisoph Capital Inc, email or visit the website at